IPCA Laboratories Limited (IPCALAB:NSE) Annual Income Statement ()
IPCALAB:NSE Quarterly Financials ()
Frequently Asked Questions About IPCA Laboratories Limited (IPCALAB:NSE) Stock
IPCA Laboratories Limited's (IPCALAB:NSE) last reported annual revenue was INR 62.44 Billion.
IPCA Laboratories Limited's (IPCALAB:NSE) annual revenue growth rate based on the revenue reported in the past 5 years is : 14.26%
IPCA Laboratories Limited's(IPCALAB:NSE) is profitable as of its last reported annual financials.
The net profit margin for IPCA Laboratories Limited's(IPCALAB:NSE) from its laster reported year is 7.55%
The return on equity (ROE) for IPCA Laboratories Limited's(IPCALAB:NSE) from its last reported annual financials is : 7.28%
The return on assets (ROA) for IPCA Laboratories Limited's(IPCALAB:NSE) from its last reported annual financials is : 4.98%
The return on invested capital (ROIC) for IPCA Laboratories Limited's(IPCALAB:NSE) from its last reported annual financials is : 6.63%
The Debt to Equity ratio for IPCA Laboratories Limited's(IPCALAB:NSE) from its last reported annual financials is : 11.16%
The dividend yield for IPCA Laboratories Limited's(IPCALAB:NSE) from its laster reported year is 0.15%
IPCA Laboratories Limited's(IPCALAB:NSE) has negative cash flow as of its last reported annual financials.
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
Poor capital utilization
The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.
Poor return on assets
The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Below median total returns
The company has under performed its peers on annual average total returns in the past 5 years.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Poor return on equity
The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.
Low Dividend Growth
This stock has shown below median dividend growth in the previous 5 years compared to its sector.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for IPCALAB:NSE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
